Rapidly proliferating cancer cells must thrive in a microenvironment wherein metabolic nutrients such as glucose, oxygen and growth factors become limiting as tumor volume expands beyond the established vascularity of the tissue. In normal cells, limits in nutrient availability trigger growth arrest and/or apoptosis thereby preventing cellular expansion under such conditions. The goal of this proposal is to determine the role of the endoplasmic reticulum stress response/Unfolded Protein Response (UPR) in sensing limitations in glucose availability and thereby facilitating cellular adaptation. PERK, one of three proximal signal transducers of the UPR plays a central role in mediating cell fate decisions. The pro-survival function of PERK has garnered it considerable interest from the point of view of developing small molecule inhibitors of its catalytic activity and the hope that such inhibitors would have potent anti-tumor activity. Indeed, in the previous funding cycle, we demonstrated that PERK inhibition is of potential clinical benefit in metastatic breast cancer. However, because PERK also pro-apoptotic and anti-proliferative activities, it could also exhibit tumor suppressive activity. Central our ability to effectively target PERK is a complete understanding of both its anti-proliferative/pro-apoptotic as well as pro-survival functions. In our preliminary work, we provide evidence that while PERK functions to facilitate melanoma progression, it paradoxically functions as a potent suppressor of melanoma initiation. In this proposal, we describe three integrated aims that focus on the elucidation of PERK function in melanoma initiation (Aim 1), the potential efficacy of anti-PERK targeted therapy (Aim 2) and the identification of tumor-derived PERK mutants and their role in tumor initiation/progression (Aim 3). These studies will provide critical new insight into the mechanisms whereby the PERK protein kinase regulates cell homeostasis in response to stress.
The aims i nterface with Projects 1 and 2 through common interests in signaling pathways that sense and respond to metabolic limitation and through response and regulation of lipid metabolism. The findings steming from work proposed herein will provide a foundation for the design of novel anti-cancer therpeutics.

Public Health Relevance

Recent work has revealed that inactivation of PERK can promote tumor progression providing support for the development of small molecule inhibitors of PERK for cancer treatment. However, our preliminary data also reveal potential tissue specific tumor suppressive properties of PERK highlighting the limited nature of our understanding of PERK regulation of cell fate. The work described in this Project will delineate molecular mechanisms of both pro- and anti-tumor properties of PERK using both chemical and genetic approaches.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA104838-11
Application #
8742522
Study Section
Special Emphasis Panel (ZCA1-RPRB-J (M1))
Project Start
2003-12-01
Project End
2019-08-31
Budget Start
2014-09-17
Budget End
2015-08-31
Support Year
11
Fiscal Year
2014
Total Cost
$261,383
Indirect Cost
$63,203
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Li, Bo; Qiu, Bo; Lee, David S M et al. (2014) Fructose-1,6-bisphosphatase opposes renal carcinoma progression. Nature 513:251-5
Mathew, Lijoy K; Skuli, Nicolas; Mucaj, Vera et al. (2014) miR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma. Proc Natl Acad Sci U S A 111:291-6
Maas, Nancy L; Singh, Nickpreet; Diehl, J Alan (2014) Generation and characterization of an analog-sensitive PERK allele. Cancer Biol Ther 15:1106-11
Fan, Jing; Ye, Jiangbin; Kamphorst, Jurre J et al. (2014) Quantitative flux analysis reveals folate-dependent NADPH production. Nature 510:298-302
Mathew, Lijoy K; Lee, Samuel S; Skuli, Nicolas et al. (2014) Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2* activity. Cancer Discov 4:53-60
Cheong, Heesun; Wu, Junmin; Gonzales, Linda K et al. (2014) Analysis of a lung defect in autophagy-deficient mouse strains. Autophagy 10:45-56
Ye, Jiangbin; Fan, Jing; Venneti, Sriram et al. (2014) Serine catabolism regulates mitochondrial redox control during hypoxia. Cancer Discov 4:1406-17
Ackerman, Daniel; Simon, M Celeste (2014) Hypoxia, lipids, and cancer: surviving the harsh tumor microenvironment. Trends Cell Biol 24:472-8
Chitnis, Nilesh; Pytel, Dariusz; Diehl, J Alan (2013) UPR-inducible miRNAs contribute to stressful situations. Trends Biochem Sci 38:447-52
Wong, Waihay J; Qiu, Bo; Nakazawa, Michael S et al. (2013) MYC degradation under low O2 tension promotes survival by evading hypoxia-induced cell death. Mol Cell Biol 33:3494-504

Showing the most recent 10 out of 52 publications